Donors make it possible to invest in both neuromuscular disorder research and care, now and for the future

FOR IMMEDIATE RELEASE – Muscular Dystrophy Canada (MDC) together with the Neuromuscular Disease Network for Canada (NMD4C) are thrilled to announce the recipients of the National Clinical and Post-doctoral Fellowships funding competition. This competition involves an extensive review by leading Canadian neuromuscular researchers and clinicians to ensure the top-ranked candidates are selected for this funding opportunity.

“Too often we hear from our community about the long and difficult process of accessing specialists or that they are unable to find information on their neuromuscular disorder, let alone access to treatments or trials. We know how critical it is to invest in the future generations of neuromuscular disorder specialists to drive research momentum forward and improve the current standard of care available in Canada,” said Stacey Lintern, CEO, Muscular Dystrophy Canada. “Together, by providing both Post-doctoral and Clinical Fellowships, we are ensuring the sustainability and progress of Canadian neuromuscular research as well as building a stronger infrastructure of skilled clinicians educated on neuromuscular disorders in Canada.”

These fellowships are made possible each year by the outstanding community of supporters who work tirelessly to support the neuromuscular community. Generous donors, passionate fundraisers and dedicated Fire Fighters across the country make it possible for MDC to fund promising researchers, ensuring Canada is prepared to provide access to new life-changing treatments, while also filling the immediate need for advanced treatment and care options by supporting future clinicians. This is a community effort and we are extremely grateful for the ongoing support. From the entire neuromuscular community, congratulations to all recipients!

Post-doctoral fellowship recipients:

Dr Yassine Ouhaddi
Centre de recherche du CHU Sainte-Justine
Montreal, QC

Dr Cedric Happi-Mbakam
SickKids Hospital
Toronto, ON

Clinical fellowship recipients:

Dr Yiu-Chia Chang
University of Western Ontario
London, ON

Dr Mark Krongold
University of British Columbia
Vancouver, BC

Dr Bram De Wel
University of Calgary
Calgary, AB

MDC and NMD4C extend special thanks to the Canadian Society of Clinical Neurophysiologists (CSCN) for jointly funding a clinical fellow this year.

Learn more about the fellowship awards

– 30 –

ABOUT MUSCULAR DYSTROPHY CANADA

Muscular Dystrophy Canada’s mission is to enhance the lives of those impacted with neuromuscular disorders by continually working to provide ongoing support and resources while relentlessly searching for a cure through well-funded research. To learn more about Muscular Dystrophy Canada, please visit muscle.ca or call our toll-free number at 1-800-567-2873.

FOR MORE INFORMATION CONTACT:

Heather Rice
Muscular Dystrophy Canada
Heather.Rice@muscle.ca
902-440-3714

RESEARCH TRAINING IS AVAILABLE FOR YOU!

Did you know you could guide research and maximize its findings? It’s true! When you become a patient research partner you will inform research findings and make a difference for the NMD community!
Many incredible NMD community members have generously participated in research initiatives as participants. But now, you can be part of the team and direct research from the inside!

Canadians affected by NMDs, their families, and advocates are often asked to take part in research, but they often feel unprepared to do so. To help you feel ready to become a research team member, Muscular Dystrophy Canada (MDC) in partnership with the Neuromuscular Disease Network for Canada (NMD4C) offers online, self-directed, free training modules through the imPORTND Patient- Oriented Research Training program.

With a ‘nothing about me, without me’ approach, MDC has been working with parent and patient partners on different projects. Most recently MDC, together with researchers from McMaster University, and research teams from Germany and Italy, were selected to conduct collaborative research project looking at the transition experiences from pediatrics to adult care for people with Duchenne muscular dystrophy (DMD) and their families. This project team includes incredible partners with lived experience such as: Doyle Steinke, Nicola Worsfold, Mark Liam Arouza Pai, Gurvir Singh Shergill, Stacy Theofilopoulos, and Andrea Cleary. Become an MDC research partner today, to participate in projects that will have a direct impact on the NMD community.

“As parents of adults with DMD and developmental disabilities, we have lived through a very frustrating transition regarding our boys’ care. From the medical side, the transition to adult care has been reasonable but from the side of caregiving and our role as caregivers, we are not being looked after like we were when the boys were minors. This is a gap that seems to plague the care system. Too many adults with complex needs fall through the cracks during the transition to adulthood. Being directly involved in this research project gives me the opportunity to make positive changes for others in similar situations.”

Doyle Victor Steinke, patient research partner

Interested in becoming a research partner? Contact us at info@muscle.ca, call 1-800-567-2873 or visit muscle.ca/services-support/advocacy/importnd/ to learn more!

Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care

Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care

For Immediate Release: June 21, 2023

Toronto, ON – The Neuromuscular Disease Network for Canada (NMD4C) has received a network grant from the Canadian Institutes of Health Research – Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA), providing funding of $200 000 per year for five years – with matched funding from Muscular Dystrophy Canada (MDC) – to strengthen the care, research and treatment of neuromuscular diseases (NMDs) for all Canadians. The new grant brings together an expanded group of clinicians, scientists and patient representatives under the leadership of Dr Hanns Lochmüller (Children’s Hospital of Eastern Ontario) and Dr Homira Osman (MDC).

“Since 2020, NMD4C has made remarkable progress in uniting Canada’s neuromuscular community. In these rare diseases, it’s crucial that we work together. We’re delighted that we have grown to more than 500 members spanning multiple disciplines, sectors, and areas of expertise. The network has made tremendous strides in building capacity through training and education, providing leadership and advocacy to improve access to approved novel treatments, and strengthening research resources and infrastructure,” explains Dr. Hanns Lochmüller, Senior Scientist, CHEO Research Institute and Professor of Neurology, University of Ottawa. “But there’s still so much more to be done. New scientific challenges and opportunities mean that networking across Canada and the globe is even more important. This new funding will allow us to expand our supportive, collaborative, networked community of neuromuscular stakeholders, bringing together an unparalleled concentration of NMD expertise to provide a Canada-wide platform for communication, collaboration, and best-practice sharing. We’re very grateful to CIHR-IMHA and MDC for the funding that allows us to continue our work. We have some really exciting plans for this next phase of the network, particularly for our young doctors and researchers, and we can’t wait to get started.”

Building on the NMD4C’s successful work over the past three years, this new grant will enable an ambitious new program of research, networking, and clinical transformation to address emerging challenges in the field of NMDs. With a total of 67 named co-investigators from across the country bringing in their wider teams of researchers, this is one of the largest networking projects in the rare disease field in Canada. Matching funds are being provided by Canada’s leading NMD advocacy organization and partner on the grant MDC, for a combined total amount of $400 000 per year of network funding.

“We greatly value our longstanding partnership with the CIHR, and are deeply thankful to our many partners, Fire Fighters, donors, volunteers and supporters who generously give so that we can fund the vital work of NMD4C,” said Dr Homira, Osman, Vice-President, Research and Public Policy, Muscular Dystrophy Canada. “In addition to offering matched funding, our role in the new grant will be to ensure evidence is translated into practices and policies that will make a tangible difference in the lives of Canadians affected by neuromuscular disorders. Aligned with our recently unveiled Breaking Down Barriers five-year strategic direction, we will partner closely with researchers, clinicians, and the neuromuscular community to enhance proactive and collaborative approaches focused on strengthening infrastructure, enhancing capacity, establishing centers of excellence, and facilitating the dissemination of research outcomes.”

This new grant unites people with lived experience, knowledge users, clinicians, and researchers to execute a new research plan with the following objectives:

Learn more “Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care”

GETTING A CLOSER LOOK AT THE SOCIAL AND ECONOMIC COSTS OF NEUROMUSCULAR DISORDERS

Muscular Dystrophy Canada is proud of our significant contributions to understanding the costs related to living with a neuromuscular disorder (NMD) in Canada. In fact, thanks to your support, we led the first study to examine the societal cost in Canada for six common types of neuromuscular disorders: Duchenne muscular dystrophy, spinal muscular atrophy, myotonic dystrophy, facioscapulohumeral muscular dystrophy, Charcot-Marie-Tooth disease, and myasthenia gravis.

What we learned is although neuromuscular disorders are rare, the total number of people with one of the six disorders mentioned above is considerable, and the total annual cost to society is substantial ($4.6 billion). It also left us wondering, what are the indirect costs for individuals affected and their families: how much time is spent in clinics and hospitals, away from work and school, and how much time and money is spent on travel, medications, rehabilitation, assistive devices and equipment, diagnostics, home therapies and other aspects of life with an NMD.

BIND, is a comprehensive new study funded by CIHR and led by Dr Jodi Warman-Chardon from the University of Ottawa, which will collect information about the hidden and indirect costs of living with any neuromuscular disorder, at any age.

Watch now: Dr Jodi Warman- Chardon leads BIND study:

With new treatments and therapies becoming available in the near future, the BIND study will be leveraged to make informed decisions to influence public policies and healthcare system planning, as well as to shape Muscular Dystrophy Canada’s programming, inform our advocacy work, and help provide information to decision-makers about what families affected by neuromuscular disorders need most.

MDC is also calling on people with myasthenia gravis (MG) to help us map the Patient Journey: What were the first signs and symptoms of MG? How long did it take to get a diagnosis? How is MG managed today?

To participate in BIND or Myasthenia Gravis: The Patient Journey in Canada, please email research@muscle.ca or call 1-800-567-2873 ext. 1114.

RAISING THE BAR FOR NEUROMUSCULAR DISORDER RESEARCH AND CLINICAL CARE IN CANADA

Thanks to Muscular Dystrophy Canada’s (MDC) incredible supporters, when opportunities arise to improve the care, research and treatment of neuromuscular disorders (NMD) for Canadians, we’re able to act. Such was the case with the Neuromuscular Disease Network for Canada (NMD4C).

Launched in January 2020, with funding from MDC and the Canadian Institutes of Health Research (CIHR), NMD4C was created to provide a comprehensive, inclusive, open and enduring network through which Canadian stakeholders can share expertise and data, and collaborate on joint activities and research. In addition to helping fund the network, MDC also became an equal partner and helps support knowledge translation.

Three years later, MDC has worked with NMD4C to:

  • introduce support for clinical and post-doctoral research fellows;
  • provide up-to-date clinical and research education through monthly accredited webinars, and forums for dialogue and exchange;
  • create a national competency standard that recognizes advanced neuromuscular training;
  • develop an accredited and standardized Canadian neuromuscular fellowship curriculum;
  • build a virtual Canadian neuromuscular disorder biobank catalogue;
  • update the Canadian Neuromuscular Disease Registry by adding two new disease datasets;
  • establish NMD clinical trials, as well as clinical trial capacity;
  • and, launch ‘imPORTND’, the first patient-oriented training platform developed specifically for neuromuscular disease research.

“Being a patient partner enables me to have meaningful input into research, to increase its relevance to quality of life and ensure that among its measures are things that are important to patients,” said Corinne Kagan, Patient Research Partner and co-developer of the imPORTND training modules.

“As a partner and funder, MDC has ensured that Canadians affected by neuromuscular disorders remain at the forefront of NMD4C’s decision making, activities and outcomes. From investing in early career researchers and clinicians and developing a virtual biobank, to strengthening the clinical landscape, the goal has always been to positively influence the NMD healthcare experience in Canada and to build research capacity and knowledge about these rare disorders,” said Dr Homira Osman, Vice President of Research and Public Policy, Muscular Dystrophy Canada. “We (MDC) remain committed to the network, and to working together to raise the bar for clinical and research standards in Canada and build upon the momentum currently taking place in research.”

Learn more about imPORTND

To learn more about NMD4C and how you can support or become involved, contact research@muscle.ca

FUNDING FOR INNOVATIVE THERAPIES FOR HEREDITARY ATAXIAS

For immediate release

Montréal, April 28, 2023 – It is with great enthusiasm that Génome Québec, Ataxia Canada and Muscular Dystrophy Canada announce the launch of the Innovative Therapies for Hereditary Ataxias competition to encourage the discovery and development of new therapies and to mobilize the research ecosystem. The three organizations aim to jointly invest $1M to support projects with a maximum of $330,000 per project for a period of two years.

The goal of this competition is to meet the needs of people affected by these rare neurological diseases, to enable them to benefit from genomic innovations and to encourage the development of innovative therapies. It supports the objectives and orientations of the provincial and federal governments, notably by accelerating therapeutic innovation (Politique québécoise pour les maladies rares) and by supporting research to improve access to affordable and effective drugs for the treatment of rare diseases.

This competition is open to researchers affiliated with a Québec university and its affiliated institutions (including hospitals and research institutes).

The deadline for submitting the mandatory registration to Génome Québec is June 8, 2023.

Learn more “FUNDING FOR INNOVATIVE THERAPIES FOR HEREDITARY ATAXIAS”

MDC funds nine new projects to propel research forward and break down barriers

Toronto, Ontario – Muscular Dystrophy Canada (MDC) is proud to announce an investment of $832,766 to fund nine new clinical and translational science research projects in 2023 through the MDC neuromuscular disorder (NMD) research grant competition, a dedicated Canadian source of funding for neuromuscular research.

“Muscular Dystrophy Canada is a leader in funding ground-breaking research for all neuromuscular disorders. This does two things: first, it lets us advance the global understanding of NMDs and the advancement of more treatments, therapies, and potential cures. And second, our involvement with these research projects means we can get people the most up-to-date information they need,” stated Stacey Lintern, CEO, Muscular Dystrophy Canada.

Drawing on the expertise of Canadian and international reviewers, including neurologists, researchers, allied health care professionals, and people with lived experience, the top projects were identified for funding.

“We held a rigorous peer-review process, and as a result, the projects selected for funding are diverse and potentially high-impact research. The projects cover different neuromuscular disorders and aspects of diagnosis, clinical care, and management and evaluate the impact on muscle function and systems outside of muscles, as well as quality of life,” said Dr. Homira Osman, Vice President, Research and Public Policy, Muscular Dystrophy Canada. She added, “supporting such projects not only contributes to the knowledge base, but it strengthens the Canadian neuromuscular research infrastructure and brings us one step closer to cures.”

The projects submitted this year for consideration were of remarkable quality, and we thank each and every team for their interest in doing this important work. MDC relies on the generosity of Fire Fighters, donors and volunteers to invest in life-changing research, and is honoured to fund the exceptional and bright researchers, clinicians and academics who will lead these nine new projects taking place in hospitals and universities across Canada.

Learn more “MDC funds nine new projects to propel research forward and break down barriers”

A Partnership to Fund Research for Hereditary Ataxias

FOR IMMEDIATE RELEASE

Montreal, February 28, 2023 – It is with great pleasure that Génome Québec, Ataxia Canada and Muscular Dystrophy Canada join forces in order to create a funding program for research on hereditary ataxias.

The goal of this program is to meet the needs of people affected by these rare neurological diseases, to allow them to benefit from genomic innovations and to encourage the development of innovative therapies. This program would support the objectives and orientations of the federal and provincial governments, notably by accelerating therapeutic innovation (Politique québécoise pour les maladies rares) and by presenting a concrete alternative for the creation of new drugs for the treatment of rare diseases (Building a National Strategy for Drugs for Rare Diseases: What We Heard from Canadians).

This partnership will not only mobilize the research community in the field, but also undertake a co-development approach in collaboration with foundations representing people affected by ataxia. This alliance will thus contribute to the democratization of research while increasing public awareness of ataxias.

This program will only be open to Québec researchers; more information will be available in the spring.

Learn more “A Partnership to Fund Research for Hereditary Ataxias”

MDC, CNDR, NMD4C partner to ensure Canadians can access FSHD cure(s)

FOR IMMEDIATE RELEASE February 28, 2023

Toronto, Ontario – Canadians affected by facioscapulohumeral muscular dystrophy (FSHD) could face substantial delays in accessing clinical trials and any Health Canada approved life-changing treatments and therapies when they become available. Muscular Dystrophy Canada (MDC), the Canadian Neuromuscular Disease Registry (CNDR), and the Neuromuscular Disease Network for Canada (NMD4C) are joining forces to help prevent that from happening.

“Studies show that Canadians have less frequent and timely access to therapies for rare diseases, like FSHD; that very few therapies approved elsewhere in the world are even submitted to Health Canada for regulatory approval; and, that if treatment is approved there is a vast difference in who has access, across the provinces,” said Stacey Lintern, CEO Muscular Dystrophy Canada.

Learn more “MDC, CNDR, NMD4C partner to ensure Canadians can access FSHD cure(s)”

First of its kind: New program will increase patient engagement in neuromuscular disorder research

Toronto, Ontario – Muscular Dystrophy Canada (MDC) and the Neuromuscular Disease Network for Canada (NMD4C) are proud to announce the launch of imPORTND, an online patient-oriented research (POR) training platform.

The imPORTND platform offers online, self-directed, free training modules on how to conduct research that is informed by, and most meaningful to individuals living with neuromuscular disorders. The modules are designed for all members of the study team: including researchers, lab staff, and patient- and family partners.

“Canadians affected by neuromuscular disorders and their families are increasingly asked to take an active role in research, but they often feel unprepared to participate,” said Dr. Homira Osman, Vice President, Research and Public Policy, Muscular Dystrophy Canada. “The training provided through imPORTND will ensure people have the confidence and knowledge needed to be involved in all stages of research: decision-making, design, planning, delivery, evaluation and knowledge mobilization. The modules will help ensure patient and family partners are well-equipped to share their lived expertise, guide discussions and inform decisions regarding health care, research, and therapy development with policymakers, industry and scientists.”

Focused on a ‘Nothing about me; without me’ patient-centred approach, imPORTND was co-developed with a team of expert patient partners, clinicians, researchers, and patient partner organization members, and is the first POR training developed specifically for neuromuscular disorder research.

“When patients and researchers collaborate on projects, the work they co-create is more meaningful and able to make real and positive impacts. Learning to work together is what ‘imPORTND’ is all about. The modules focus on the tools, skills and relationships needed by researchers, patient-partners and clinicians to partner for work that is more inclusive, equitable, diverse and accessible.,” said Dr. Kathryn Selby, Medical Director, Pediatric Neuromuscular Program of BC and the Yukon and Patient-Oriented Resources Lead Investigator at the Neuromuscular Disease Network for Canada.

The neuromuscular community is excited to participate in projects that impact them directly.

“As patient partners, our voices give deeper understanding to neuromuscular conditions, with each one of us sharing our unique lived experiences. Together with medical research teams, we prioritize meaningful timely research that immediately serves to improve quality of life,” said Linda Niksic, NMD4C Patient Research Partner, and contributor to the imPORTND training modules.

Additional information about imPORTND, can be found at importnd.neuromuscularnetwork.ca.

-30-

ABOUT MUSCULAR DYSTROPHY CANADA

Muscular Dystrophy Canada’s mission is to enhance the lives of persons affected by neuromuscular disorders by continually working to provide ongoing support and resources while relentlessly searching for cures through well-funded research. To learn more about MDC, please visit muscle.ca or call our toll-free number at 1-800-567-2873.

MEDIA CONTACT

Heather Rice
Muscular Dystrophy Canada
Heather.Rice@muscle.ca
902-440-3714